{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:32:39Z","timestamp":1790937159479,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:00:00Z","timestamp":1607212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Research Foundation of South Africa","award":["109437"],"award-info":[{"award-number":["109437"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK Department for International Development","award":["MR\/R007942\/1"],"award-info":[{"award-number":["MR\/R007942\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Much of the neurological sequelae of central nervous system (CNS) tuberculosis (TB) is due to an excessive cytokine-driven host-inflammatory response. Adjunctive corticosteroids, which reduce cytokine production and thus dampen the inflammation, improve overall survival but do not prevent morbidity. This has prompted investigation of more targeted immunomodulatory agents, including thalidomide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We describe a retrospective cohort of 38 children consecutively treated with adjunctive thalidomide for CNS TB\u2013related complications over a 10-year period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most common presenting symptom was focal motor deficit (n\u2005=\u200516), followed by cranial nerve palsies and cerebellar dysfunction. Three of the 38 children presented with large dural-based lesions, manifesting as epilepsia partialis continua (EPC), 4 presented with blindness secondary to optochiasmatic arachnoiditis, and 2 children developed paraplegia due to spinal cord TB mass lesions. Duration of adjunctive thalidomide therapy (3\u20135 mg\/kg\/day) varied according to complication type. In children compromised by TB mass lesions, the median treatment duration was 3.9 months (interquartile range [IQR], 2.0\u20135.0 months), whereas in children with optic neuritis it was 2.0 months (IQR, 1.3\u20137.3 months) and in EPC it was 1.0 months (IQR, 1\u20132.5 months). Satisfactory clinical and radiological response was observed in 37 of the children. None of the children experienced rashes, hepatitis, or hematologic derangements or complained of leg cramps.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study is the largest cohort of adult or pediatric patients treated with adjunctive thalidomide for CNS TB\u2013related complications. The drug has proved to be safe and well tolerated and appears to be clinically efficacious. The potential role of thalidomide or analogues in the treatment of other tuberculous meningitis\u2013related complications requires further exploration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1826","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:18:34Z","timestamp":1607026714000},"page":"e136-e145","source":"Crossref","is-referenced-by-count":42,"title":["Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort"],"prefix":"10.1093","volume":"72","author":[{"given":"Ronald","family":"van Toorn","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-8443","authenticated-orcid":false,"given":"Regan S","family":"Solomons","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Seddon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Imperial College London, London, United Kingdom"},{"name":"Desmond Tutu Tuberculosis Centre, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan F","family":"Schoeman","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,6]]},"reference":[{"key":"2021030519533053300_CIT0001","volume-title":"Global tuberculosis report 2020","year":"2020"},{"key":"2021030519533053300_CIT0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2021030519533053300_CIT0003","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","article-title":"Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis","volume":"14","author":"Chiang","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2021030519533053300_CIT0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2008-1353","article-title":"Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa","volume":"123","author":"van Well","year":"2009","journal-title":"Pediatrics"},{"key":"2021030519533053300_CIT0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1542\/peds.99.2.226","article-title":"Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis","volume":"99","author":"Schoeman","year":"1997","journal-title":"Pediatrics"},{"key":"2021030519533053300_CIT0006","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"2021030519533053300_CIT0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"key":"2021030519533053300_CIT0008","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"2021030519533053300_CIT0009","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2040620711413165","article-title":"The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development","volume":"2","author":"Rehman","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"2021030519533053300_CIT0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/08892220050140892","article-title":"Thalidomide for the treatment of AIDS-associated wasting","volume":"16","author":"Kaplan","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021030519533053300_CIT0011","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.46.6.1887-1895.2002","article-title":"Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis","volume":"46","author":"Tsenova","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2021030519533053300_CIT0012","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/088307380001500801","article-title":"Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role","volume":"15","author":"Schoeman","year":"2000","journal-title":"J Child Neurol"},{"key":"2021030519533053300_CIT0013","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/088307380401900402","article-title":"Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study","volume":"19","author":"Schoeman","year":"2004","journal-title":"J Child Neurol"},{"key":"2021030519533053300_CIT0014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/08830738060210040801","article-title":"Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases","volume":"21","author":"Schoeman","year":"2006","journal-title":"J Child Neurol"},{"key":"2021030519533053300_CIT0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/INF.0000000000000539","article-title":"Clinicoradiologic response of neurologic tuberculous mass lesions in children treated with thalidomide","volume":"34","author":"van Toorn","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"2021030519533053300_CIT0016","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/0883073809350507","article-title":"Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases","volume":"25","author":"Schoeman","year":"2010","journal-title":"J Child Neurol"},{"key":"2021030519533053300_CIT0017","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(10)70138-9","article-title":"Tuberculous meningitis: a uniform case definition for use in clinical research","volume":"10","author":"Marais","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2021030519533053300_CIT0018","first-page":"582","article-title":"Streptomycin treatment of tuberculous meningitis","volume":"1","year":"1948","journal-title":"Lancet"},{"key":"2021030519533053300_CIT0019","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ejpn.2012.04.005","article-title":"Neurological manifestations of TB-IRIS: a report of 4 children","volume":"16","author":"van Toorn","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"2021030519533053300_CIT0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.spen.2014.01.006","article-title":"Update on the diagnosis and management of tuberculous meningitis in children","volume":"21","author":"van Toorn","year":"2014","journal-title":"Semin Pediatr Neurol"},{"key":"2021030519533053300_CIT0021","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/323806","article-title":"The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children","volume":"184","author":"Hanekom","year":"2001","journal-title":"J Infect Dis"},{"key":"2021030519533053300_CIT0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ebiom.2017.08.007","article-title":"Thalidomide is associated with increased T cell activation and inflammation in antiretroviral-naive HIV-infected individuals in a randomised clinical trial of efficacy and safety","volume":"23","author":"Vergara","year":"2017","journal-title":"EBioMedicine"},{"key":"2021030519533053300_CIT0023","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/187152809787582543","article-title":"TNF-alpha in tuberculosis: a cytokine with a split personality","volume":"8","author":"Mootoo","year":"2009","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2021030519533053300_CIT0024","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021030519533053300_CIT0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/clinids\/21.4.924","article-title":"Concentrations of interferon gamma, tumor necrosis factor alpha, and interleukin-1 beta in the cerebrospinal fluid of children treated for tuberculous meningitis","volume":"21","author":"Donald","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2021030519533053300_CIT0026","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/01.inf.0000131634.57368.45","article-title":"Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis","volume":"23","author":"van der Flier","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2021030519533053300_CIT0027","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1042\/CS20190415","article-title":"Revisiting hypoxia therapies for tuberculosis","volume":"133","author":"Oehlers","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"2021030519533053300_CIT0028","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/joim.12256","article-title":"Inflammation and tuberculosis: host-directed therapies","volume":"277","author":"Zumla","year":"2015","journal-title":"J Intern Med"},{"key":"2021030519533053300_CIT0029","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity","volume":"2","author":"Corral","year":"1996","journal-title":"Mol Med"},{"key":"2021030519533053300_CIT0030","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"2021030519533053300_CIT0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/pmj.79.929.127","article-title":"Thalidomide and its derivatives: emerging from the wilderness","volume":"79","author":"Gordon","year":"2003","journal-title":"Postgrad Med J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1826\/35373835\/ciaa1826.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/5\/e136\/36415760\/ciaa1826.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/5\/e136\/36415760\/ciaa1826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T20:05:21Z","timestamp":1614974721000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/5\/e136\/6024997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,6]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,12,6]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1826","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,12,6]]}}}